Frequency of oropharyngeal candidiasis in HIV-infected patients on protease inhibitor therapy

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

Volumn 87, Issue 4, 1999, Pages 437-441

  Diz Dios, P ^a,c   Ocampo, A ^b   Miralles, C ^b   Otero, I ^b   Iglesias, I ^b   Rayo, N ^b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b Xeral Cies Hospital   (Spain)

^c NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; ENZYMOLOGY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LEUKOCYTE COUNT; MALE; THRUSH; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; CANDIDIASIS, ORAL; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LEUKOCYTE COUNT; MALE; VIRAL LOAD;

EID: 0033112644     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1079-2104(99)70242-8     Document Type: Article

References (38)

1. Murphy M, Armstrong D, Sepkowitz KA, Ahkami RN, Myskowski PL. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor. AIDS 1997;11:261-2.
2. Conant MA, Opp KM, Poretz D, Mills RG. Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonovir. AIDS 1997;11:1300-1.
3. Elliot B, Aromin I, Gold R, Flanigan T, Mileno M. 2.5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy. Lancet 1997;349:850.
4. Contamin B, Boibieux A, Gerard-Boncompain M, Bouhour D, Girault V, Biron-Peyramond D. Infection a Cryptosporidium: interet d' un inhibiteur de protease. Presse Med 1997;26:416.
5. Grube H, Ramratnam B, Ley C, Flanigan TP. Resolution of AIDS-associated cryptosporidiosis after treatment with indinavir. Am J Gastroenterol 1997;92:726.
6. Zingman BS. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir. N Engl J Med 1996;334:1674-5.
7. Hood S, Bonington A, Evans J, Denning D. Reduction in oropharyngeal candidiasis following introduction of protease inhibitors. AIDS 1998;12:447-8.
8. Valdez H, Gripshover BM, Salata RA, Lederman MM. Resolution of azole-resistant oropharyngeal candidiasis after initiation of potent combination antiretroviral therapy. AIDS 1998;12:538.
9. Greenspan JS. Sentinels and signposts: the epidemiology and significance of the oral manifestations of HIV disease. Oral Diseases 1997;3(Suppl 1):S13-S17.
10. EC Clearinghouse on Oral Problems Related to HIV Infection and WHO Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus. Classification and diagnostic criteria for oral lesions in HIV infection. J Oral Pathol Med 1993;22:289-91.
11. Greenfield RA. Host defense system interactions with Candida. J Med Vet Mycol 1992;30:89-104.
12. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997;277:145-53.
13. Gabrilovich DI, Vassilev V, Nosikov W, Serebrovkaya LV, Ivanova LA, Pokrovsky W. Clinical significance of HIV DNA in polymorphonuclear neutrophils from patients with HIV infection. J Acquir Immune Defic Syndr 1993;6:587-91.
14. Busch M, Beckstead J, Gantz D, Vyas G. Detection of human immunodeficiency virus infection of mieloid precursors in bone marrow samples from AIDS. Blood 1986;68(Suppl 1):122a.
15. Gabrilovich DI, Kozhich AT, Suvorova ZK, et al. Influence of HIV antigens on functional activity of neutrophilic granulocytes. Scand J Immunol 1991;33:549-52.
16. Novak MA, McMichael AJ. How HIV defeats the immune system. Sci Am 1995;8:58-65.
17. Gómez M J, Torosantucci A, Arancia S, Maras B, Parisi L, Cassone A. Purification and biochemical characterization of a 65 kilodalton mannoprotein (MP65), a main target of anti-Candida cell-mediated immune responses in humans. Infect Immun 1996;64:2577-84.
18. Senet JM. Risk factors and physiopathology of candidiasis. Revista Iberoamericana de Micologia 1997;14:6-13.
19. Tascini C, Baldelli F, Monari C, et al. Inhibition of fungicidal activity of polymorphonuclear leukocytes from HIV-infected patients by interleukin (IL)-4 and IL-10. AIDS 1996;10:477-83.
20. Clereci M, Shearer GM. A Th1-Th2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107-11.
21. Cohen J. T cell shift: key to AIDS therapy. Science 1993;262:175-6.
22. Dale DC. Physiology, function, and role of the neutrophil in host defense. Scientific Therapeutics Information. Amgen, Inc; 1994. p. 24-5.
23. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
24. Gray CM, Schapiro JM, Winters MA, Merigan TC. Changes in CD4+ and CDS+ T cell subsets in response to highly active anti-retroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. AIDS Res Hum Retroviruses 1998;14:561-9.
25. Carr A, Emery S, Kelleher A, Law M, Cooper DA. CDS+ lymphocyte responses to antiretroviral therapy of HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13:320-6.
26. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996;173:321-9.
27. Swerdloff JN, Filler SG, Edwards JE. Severe candidal infections in neutropenic patients. Clin Infect Dis 1993;17(Suppl 2):S457-S467.
28. Moreno Garcia M. Neutropenia in human immunodeficiency virus infection [in Spanish). Ann Med Intern (Madrid) 1997; 14:199-208.
29. Zon LI, Arkin C, Groopman JE. Haematologic manifestations of the human immune deficiency virus. Br J Haematol 1987;66:251-6.
30. Vecchiarelli A, Monari C, Baldelli F, et al. Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphonuclear leukocytes from patients with AIDS. J Infect Dis 1995;171:1448-54.
31. Vaone FH, Payan DG, Abrams DI, Goetzl EJ. Defective polymorphonuclear leukocyte chemotaxis in homosexual men with persistent lymph node syndrome. J Infect Dis 1984;150:267-71.
32. Ellis M, Gupta S, Galant S, et al. Impaired neutrophil function in patients with AIDS or AIDS-related complex: a comprehensive evaluation. J Infect Dis 1988;158:1268-76.
33. Wenisch CH, Parschalk B, Zedwitz-Liebenstein K, Graniger W, Rieger A. Dysregulation of the polymorphonuclear leukocyte-Candida spp. interaction in HIV-positive patients. AIDS 1996;10:983-7.
34. Kimura S, Matsuda J, Ikematsu S, et al. Efficacy of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with AIDS. AIDS 1990;4:1251-5.
35. Scadden DT. The use of GM-CSF in AIDS. Infection 1992;20(Suppl 2):S103-S106.
36. Capetti A, Bonfanti P, Magni C, Milazzo F. Employment of recombinant human granulocyte-macrophage colony stimulating factor in oesophageal candidiasis in AIDS patients. AIDS 1995;9:378-9.
37. Tozzi V, Narcisco P, Sebastiani G, Frigiotti D, D'Amato C. Effects of indinavir treatment on platelet and neutrophil counts in patients with advanced HIV disease. AIDS 1997;11:1067-8.
38. Lloyd AR, Oppenheim JJ. Poly's lament: the neglected role of the polymorphonuclear neutrophil in the afferent limb of the immune response. Immunol Today 1992;13:169-72.